Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourBearish
15 minBearish
5 minConsolidating
Daily trend turns down below $195.14
Key levels
Resistance$268.74
Resistance$255.66
Support$241.39
Support$234.34
Latest news & SEC filings
NewsSTERIS Registers Securities for Future Offerings
AnalystKeybanc keeps Overweight rating on Steris, lifts price target to $284
SEC FilingSTERIS plc filed an automatic shelf registration for future offerings (Form S-3ASR)
All STE news →STERIS provides infection prevention products and services for healthcare and life science customers worldwide. Its Healthcare segment supplies sterile processing consumables, surgical and endoscopy equipment, instrument repair, and outsourced reprocessing to hospitals and surgery centers. The Applied Sterilization Technologies segment offers contract sterilization and lab testing to medical device and pharmaceutical makers. The Life Sciences segment serves biopharmaceutical and medical device manufacturers with cleanroom products, sterilizers, and equipment service.
Based on the company's 10-K filed May 29, 2026.
NYSE · Healthcare
SEPT Low Target
$270.00
SEPT Mid Target
$275.00
SEPT High Target
$284.00
Analyst Consensus
$275.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for STE.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, Analyst Consensus
Fair Value
$255.76
56
Moat Score
NARROW
9/9
Piotroski Score
5.7
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
BUYING
11 buys / 9 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Burton Karen L | officer | Sale | 228 | - | Oct 1, 2026 |
| Carestio Daniel A | director officer | Sale | 1,374 | $291K | Jun 5, 2026 |
| Zangerle John Adam | officer | Sale | 401 | $85K | Jun 4, 2026 |
| Tamaro Renato | officer | Sale | 65 | $14K | Jun 4, 2026 |
| Madsen Julia | officer | Sale | 195 | $41K | Jun 4, 2026 |
| Kohler Kenneth E | officer | Sale | 150 | $32K | Jun 4, 2026 |
| Fraser Mary Clare | officer | Sale | 600 | $127K | Jun 4, 2026 |
| Carestio Daniel A | director officer | Sale | 1,889 | $401K | Jun 4, 2026 |
| Carestio Daniel A | director officer | Sale | 3,054 | $656K | Jun 4, 2026 |
| Burton Karen L | officer | Sale | 90 | $19K | Jun 4, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
8.7%
3yr Revenue CAGR
9.4%
EPS Growth YoY
27.9%
FCF Growth YoY
25.0%
Revenue Trend
STABLE
SEPT Investing tracks real-time dark pool institutional trades for STE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:28:26 | $256.27 | 1,512 | $$387K | BUY |
| 21:00:26 | $256.27 | 2,840 | $$728K | BUY |
| 21:00:14 | $256.27 | 46,533 | $$11.9M | BUY |
| 21:00:11 | $256.27 | 3,011 | $$772K | BUY |
| 20:15:37 | $256.23 | 1,030 | $$264K | BUY |
5 dark pool trades shown · $$14.1M preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for STERIS plc (STE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →STERIS plc (STE) is at $253.44, down 1.10% (-$2.83) at the Nov 12, 2026 close.
Latest STE news — Nov 6, 2026: STERIS Registers Securities for Future Offerings · Nov 6, 2026: Keybanc keeps Overweight rating on Steris, lifts price target to $284
STERIS shares rose 3.08% to close at $247.91 after the company reported Q2 adjusted earnings of $2.94 per share, beating the $2.68 consensus, with revenue of $1.589 billion also topping the $1.562 billion estimate. The company also lifted its FY2027 adjusted EPS outlook to $11.35-$11.55 from $11.00-$11.30, above the $11.18 consensus, though it trimmed its FY2027 sales guidance to $6.352B-$6.411B versus the $6.373B estimate.
The average analyst price target for STE is $275.00, ranging from $270 to $284, based on 3 analysts. Latest: Keybanc maintains on Nov 6, 2026.
Analyst ratings for STE: 1 Buy, 4 Hold, 0 Sell — consensus Hold.
STE last reported on Nov 4, 2026: EPS $2.19 vs $2.67 expected — a miss of 18.0%.
Yes. STE's dividend yield is 0.98%.
STERIS plc reported $1.7B of debt and $531M of cash (Sep 30, 2026).
Support: $241.39, $234.34, $225.01. Resistance: $255.66, $268.74.
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
Nov 6, 2026: STERIS Registers Securities for Future Offerings · Nov 6, 2026: Keybanc keeps Overweight rating on Steris, lifts price target to $284 · Nov 6, 2026: STERIS plc filed an automatic shelf registration for future offerings (Form S-3ASR)